Who is this for?
This is for people with locally advanced rectal cancer — a rectal cancer that has grown into or through the rectal wall, or reached nearby lymph nodes (stage II or III), but has not spread to distant organs.
The standard cure for this has three parts: chemoradiation, then surgery to remove the rectum, then more chemotherapy. That surgery is effective, but it is big — it can permanently affect bowel, bladder, and sexual function, and for cancers low in the rectum it often means a permanent colostomy (a bag). Understandably, many people want to avoid it if they safely can.
What kind of trial is this?
OPRA was a randomized phase II trial at 18 US centers. Everyone received total neoadjuvant therapy; the trial randomly assigned the order of the treatments, and then used a watch-and-wait strategy for those whose tumors responded well — measuring how many could keep their rectum, and whether their cancer outcomes held up.
Background: can we skip the surgery?
Doctors had noticed that in some people, chemoradiation melts a rectal tumor away completely. That raised a bold question: if the cancer appears to be gone, does the rectum still have to be removed — or could the patient simply be watched closely, and only have surgery if the cancer came back?
The catch is that a standard course of chemoradiation only clears the tumor completely in a minority of people. OPRA’s idea was to give more treatment up front — all the chemotherapy and the chemoradiation before any surgery decision — to melt away more tumors, and so give more people the chance to keep their rectum.
The trial: what was tested and how
OPRA enrolled 324 people with stage II or III rectal cancer. Everyone received total neoadjuvant therapy, and they were randomly assigned to one of two orders:
- Induction first: chemotherapy, then chemoradiation.
- Consolidation: chemoradiation, then chemotherapy.
After the treatment, each tumor was carefully restaged. People with a complete or near-complete response were offered watch-and-wait (close surveillance instead of surgery); those with residual tumor were advised to have surgery. The key questions were how many could keep their rectum, and whether cancer outcomes (disease-free survival) held up compared with the historical standard.
Results: what they found
About half of patients were able to keep their rectum — and doing so did not appear to cost them anything in cancer control.
Total neoadjuvant therapy + selective watch-and-wait
Roughly half kept their own rectum and avoided major surgery. Giving the chemoradiation first and the chemotherapy afterward (consolidation) preserved the rectum more often.
Cancer outcomes were the same as the traditional surgery-first approach. Preserving the rectum did not appear to trade away survival.
About a third of watch-and-wait patients had the tumor regrow — almost always caught by surveillance. Those who then had surgery had the same disease-free survival as people operated on from the start.
What does “watch-and-wait” actually involve?
It is not just waiting — it is intensive surveillance. In OPRA that meant a rectal exam and a look inside with a scope every few months, plus rectal MRI scans, for years, so that any regrowth is caught early while it is still small and curable. It asks real commitment from the patient, and it works best at centers experienced in this approach.
Which order is better — induction or consolidation?
Both gave the same cancer survival, but giving the chemoradiation first and the chemotherapy afterward (“consolidation”) let more people keep their rectum (53% vs 41% at 3 years). On the strength of this, the consolidation order became the preferred way to give total neoadjuvant therapy when organ preservation is the goal.
Is it risky to delay surgery?
This was the central worry, and OPRA is reassuring on it: patients whose cancer regrew and who then had surgery did just as well as those who had surgery up front. The key is strict surveillance, so regrowth is found early. Watch-and-wait is not right for everyone — it requires a strong response to treatment and a commitment to close follow-up — but for suitable people it can safely avoid a life-changing operation.
The bottom line
For locally advanced rectal cancer, OPRA showed that giving all the chemotherapy and radiation first, then watching closely, let about half of patients keep their rectum and avoid major surgery — with the same cancer survival as the traditional surgery-first approach (about 76% disease-free at 3 years). Giving the chemoradiation before the chemotherapy preserved the rectum more often. This has made organ preservation a real, evidence-based option for people who respond well and are willing to commit to close surveillance.
What this could mean for you
- Keeping the rectum may be possible. If you have locally advanced rectal cancer, ask whether total neoadjuvant therapy and a watch-and-wait approach could be options for you.
- It depends on the response. Only people whose tumor melts away completely (or nearly so) can safely avoid surgery — about half in this trial.
- Surveillance is the safety net. Watch-and-wait means frequent exams, scopes, and scans; regrowth caught early can still be cured with surgery.
- Surgery is still the right answer for many. An incomplete response means surgery remains the safest path — and outcomes are still good.
Questions & comments
Have a question about this research? Ask below. Questions are read and answered by the site. We can’t give personal medical advice, but we’re glad to explain the research more clearly.